

1 SUPPLEMENTARY DATA TO

2 **Antimicrobial and Anti-Tubercular Activities of Isolates and Semi-synthetic Derivatives of**
3 **Lichen *Ramalina leiodea* (Nyl.) Nyl.**

4 VINAY BHARADWAJ TATIPAMULA and GIRIJA SASTRY VEDULA*

5 *Pharmaceutical Chemistry Department, University College of Pharmaceutical Sciences, Andhra*
6 *University, Visakhapatnam – 530 003, Andhra Pradesh, India.*

7 *Corresponding author. E-mail: vgirijasastry@yahoo.co.in

8 EXPERIMENTAL

9 *Antimicrobial Activities*

10 Both the antibacterial and antifungal activities for measuring antimicrobial properties
11 were carried out according to standard well plate method¹. For antibacterial activity all the
12 selected test strains (*Salmonella typhi*, *Pseudomonas aeruginosa*, *Bacillus subtilis* and
13 *Staphylococcus aureus*) were initially activated and grown in nutrient agar. Whereas for
14 antifungal studies test strain used, *Candida albicans* were grown on the potato dextrose agar
15 medium. All compounds were re-dissolved in DMSO to get a final concentration of 1 mg/mL
16 and used as stock solution. The compounds were used for activity studies and the concentration
17 of each sample is 1 µg/mL along with standard and control. The media, Petri dishes were
18 autoclaved at 121°C for 15 min. After sterilization the agar plates were prepared by pouring 25
19 mL of agar medium followed by incubation at room temperature for 30 min for solidification
20 under sterile environment. These plates were inoculated with 60 µL of test inoculums using
21 sterile cotton swabs. An 8 mm width size wells were made with sterile cork borer and in each
22 well exactly 100 µL of sample were loaded. Control and standard also placed in separate wells.
23 The plates were initially incubated for 20-30 min at 4°C to allow the compounds to diffuse into
24 the agar, and then subsequently incubated for 24 h at 37°C for bacteria and 48 h at 28°C for
25 fungi. Zone diameters were expressed in mm using calibrated scale. Experiments were conducted
26 in triplicate with aliquots to minimize the deviations and the average values were reported.

27 The compounds having better anti-microbial activity were selected for the minimum
28 inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) studies against
29 the *Salmonella typhi*, *Pseudomonas aeruginosa*, *Bacillus subtilis*, *Staphylococcus aureus* and


30 *Candida albicans* according to reported method². The concentrations of test samples were
31 serially diluted from 1 to 0.001 µg/mL and one tube without drug served as control. All the tubes
32 were inoculated with 1 mL of respective cultures having an OD of 0.2 (~McFarland standard)
33 and the tubes were incubated at 37°C for 12-16 h. The turbidity of each tube is measured with
34 respect to control tube. MIC values are defined as the lowest concentration of compound at
35 which growth is completely inhibited. After incubation the culture from each tube was plated in
36 nutrient agar to evaluate the MBC concentration. The concentration at which the cells are
37 completely dead was defined as MBC.

38 *Anti-tubercular Activity*

39 The *in vitro* anti-tubercular activity assessment of all compounds have been tested against
40 *Mycobacterium tuberculosis* H37Rv strain ATCC 27294 using microplate alamar blue assay
41 (MABA)^{2,3} in three sets (n=3). The Minimum Inhibitory Concentration (MIC) value was
42 determined by a colour change of blue to pink which indicates no bacterial growth and growth,
43 respectively.


44 RESULTS

45 *Chemistry*



46 **1**


47 *Usnic acid (1)*. Product yield: 236 mg (0.16%), MP: 201-202°C, Rf: 0.4 (Hexane-DCM,
48 9:1). IR (KBr): 2923, 2858, 1687, 1626, 1543, 1462, 1368, 1293, 1192, 1138, 1071, 1037, 966,
49 843 cm⁻¹. UV/Vis λ_{max} (EtOH) nm (log ε): 220. ¹H NMR (400 MHz, CDCl₃): 1.76 (3H, s, Me-
50 13), 2.11 (3H, s, Me-16), 2.67 (3H, s, Me-15), 2.68 (3H, s, Me-18), 5.98 (1H, s, H-4), 11.03 (1H,
51 s, OH-10), 13.31 (1H, s, OH-8). ¹³C NMR (400 MHz, CDCl₃): 7.6 (CH₃, C-16), 27.9 (CH₃, C-
52 13), 31.3 (CH₃, C-18), 32.2 (CH₃, C-15), 59.1 (C, C-12), 98.4 (CH, C-4), 101.6 (C, C-7), 104.0
53 (C, C-11), 105.3 (C, C-2), 109.3 (C, C-9), 155.2 (C, C-6), 157.5 (C, C-10), 163.9 (C, C-8), 179.4
54 (C, C-5), 191.7 (C, C-3), 198.1 (C, C-1), 200.4 (C, C-14), 201.8 (C, C-17). MS (EI, 70 eV): *m/z*
55 (%) = 343 [M-H⁺] (100), 345 [M+H⁺] (100). HRMS-FAB: *m/z* [M + H⁺] calcd for C₁₈H₁₆O₇:
56 344.09; found: 344. Anal. Calcd for C₁₈H₁₆O₇: C, 63.15; H, 6.26. Found C, 63.16; H = 6.26.



2

57


58 *Ethyl everninate* (2). Product yield: 153 mg (0.10%). MP: 74-76°C, Rf: 0.4 (Hexane-
 59 DCM, 7:3), IR (KBr): 2920, 2855, 1625, 1462, 1371, 1280, 1243, 1164, 757 cm^{-1} . UV/Vis λ_{max}
 60 (EtOH) nm (log ϵ): 219. ^1H NMR (400 MHz, Acetone- d_6): 0.95 (3H, t, Me-9), 1.62 (2H, m, CH₂-
 61 8), 2.06 (3H, t, Me-11), 2.09 (H, s, OH-2), 3.83 (3H, s, OMe-10), 6.33 (1H, d, H-5), 6.37 (1H, d,
 62 H-3). ^{13}C NMR (400 MHz, Acetone- d_6): 14.47 (CH₃, C-9), 25.85 (CH₃, C-11), 54.96 (CH₃, C-
 63 10), 55.8 (CH₂, C-8), 99.7 (C, C-1), 111.1 (CH, C-3/5), 149.1 (C, C-6), 165.2 (C, C-2), 167.2 (C,
 64 C-4), 174.0 (C, C-7). MS (EI, 70 eV): m/z (%) = 209.1 [M-H⁺] (100), 211 [M+H⁺] (100).
 65 HRMS-FAB: m/z [M + H⁺] calcd for C₁₁H₁₄O₄: 210.09; found: 210. Anal. Calcd for C₁₁H₁₄O₄:
 66 C, 62.85; H, 6.71. Found C, 62.87; H = 6.82.



3

67


68 *Scrobiculin* (3). Product yield: 911 mg (0.61%), MP: 134-136°C, Rf: 0.6 (DCM-EA, 7:3),
 69 IR (KBr): 2958, 2926, 2864, 1657, 1619, 1581, 1503, 1455, 1420, 1342, 1239, 1160, 1129, 1088,
 70 1037, 830, 757 cm^{-1} . UV/Vis λ_{max} (EtOH) nm (log ϵ): 217.5. ^1H NMR (400 MHz, DMSO- d_6):
 71 0.88-0.97 (6H, m, Me-9,9'), 1.59-1.65 (4H, dd, CH₂-8, 8'), 2.51 (1H, t, OH-2), 2.82-2.87 (4H,
 72 dd, CH₂-7,7'), 3.78 (3H, s, OMe-10), 3.84 (3H, s, OMe-10'), 6.39-6.41 (2H, dd, H-3,5), 6.61
 73 (1H, s, H-16), 10.50 (1H, s, OH-17), 11.85 (1H, s, OH-13). ^{13}C NMR (400 MHz, DMSO- d_6):
 74 14.5 (CH₃, C-9), 14.6 (CH₃, C-9'), 24.8 (CH₂, C-8), 25.2 (CH₂, C-8'), 36.9 (CH, C-7), 37.8 (CH,
 75 C-7'), 55.8 (CH₃, C-10), 56.5 (CH₃, C-10'), 99.5 (CH, C-3), 106.2 (CH, C-1), 108.6 (CH, C-16),
 76 108.8 (C, C-14), 109.5 (CH, C-5), 125.2 (C, C-12), 144.1 (C, C-15), 146.0 (C, C-6), 154.3 (C, C-
 77 13), 154.7 (C, C-17), 160.6 (C, C-2), 162.9 (C, C-4), 166.7 (C, C-11), 172.7 (C, C-18). MS (EI,
 78 70 eV): m/z (%) = 417 [M-H⁺] (100), 418.9 [M+H⁺] (100). HRMS-FAB: m/z [M + H⁺] calcd for
 79 C₂₂H₂₆O₈: 418.44; found: 418. Anal. Calcd for C₂₂H₂₆O₈: C, 63.15; H, 6.26. Found C, 63.16; H =
 80 6.26.



4


81

82 *Methyl 2,6-dihydroxy-4-methylbenzoate (4)*. Product yield: 4.05 g (2.70%), MP: 143-
 83 144°C, Rf: 0.6 (Hexane-EA, 1:1), IR (KBr): 3866, 3746, 3370, 3312, 2982, 2955, 2854, 1894,
 84 1642, 1581, 1503, 1447, 1383, 1318, 1265, 1197, 1162, 1114, 1059, 1029, 996, 950, 835, 800,
 85 753, 700, 620, 575 cm⁻¹. UV/Vis λ_{max} (EtOH) nm (log ε): 219.5. ¹H NMR (400 MHz, DMSO-
 86 *d*₆): 2.23 (3H, s, Me-9), 3.75 (3H, s, OMe-8), 6.12 (2H, d, H-3, 5), 9.94 (1H, s, OH-6), 10.65
 87 (1H, s, OH-2). ¹³C NMR (400 MHz, DMSO-*d*₆): 22.5 (C-9), 52.2 (C-8), 100.8 (C-1), 107.9 (C-
 88 5), 110.6 (C-3), 141.2 (C-4), 161.5 (C-2/6), 170.6 (C-7). MS (EI, 70 eV): *m/z* (%) = 183.0 [M +
 89 H⁺] (100). HRMS-FAB: *m/z* [M + H⁺] calcd for C₉H₁₀O₄: 182.18; found: 182. Anal. Calcd for
 90 C₉H₁₀O₄: C, 59.34; H, 5.53. Found C, 59.36; H = 5.52.




5

91
 92 *2'-O-methyldivaricatic acid (5)*. Product yield: 11 mg (0.007%), MP: 142-143°C, Rf: 0.4
 93 (Hexane-EA, 1:1), UV/Vis λ_{max} (EtOH) nm (log ε): 212.5. ¹H NMR (400 MHz, CDCl₃): 0.93-
 94 1.05 (6H, m, Me-9, 9'), 1.66-1.80 (4H, m, CH₂-8, 8'), 2.95-3.04 (4H, m, CH₂-7, 7'), 3.85 (3H, s,
 95 OMe-10), 3.91 (3H, s, OMe-10'), 6.40 (2H, s, H-13, 17), 6.46 (2H, s, H-3, 5), 11.18 (1H, s, OH-
 96 18), 11.73 (1H, s, OH-2). ¹³C NMR (400 MHz, CDCl₃): 14.3 (CH₃, C-9/9'), 24.81 (CH₂, C-8'),
 97 25.18 (CH₂, C-8), 38.8 (CH, C-7'), 39.1 (CH, C-7), 55.4 (CH₃, C-10), 56.0 (CH₃, C-10'), 99.8
 98 (CH, C-3), 104.5 (C, C-1), 106.2 (C, C-15), 107.1 (CH, C-13), 110.9 (CH, C-5), 146.8 (CH, C-
 99 17), 148.7 (C, C-16), 151.6 (C, C-6), 156.1 (C, C-12), 156.9 (C, C-14), 164.4 (C, C-4), 165.5 (C,
 100 C-2), 168.9 (C, C-11), 173.7 (C, C-18). MS (EI, 70 eV): *m/z* (%) = 403.53 [M - H⁺] (100).
 101 HRMS-FAB: *m/z* [M + H⁺] calcd for C₂₂H₂₆O₇: 402.17; found: 402.53. Anal. Calcd for
 102 C₂₂H₂₆O₇: C, 65.66; H, 6.51. Found C, 65.66; H = 6.62.



4a


103
 104 *2,6-dihydroxy-4-methylbenzohydrazide (4a)*. Product yield: 77%, MP: 153-154°C. IR
 105 (KBr): 2917, 2564, 1621, 1498, 1458, 1367, 1325, 1266, 1216, 1173, 1001, 919, 841, 800, 735,
 106 688 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): 2.57 (*s*, 3H, Me), 5.07 (*s*, 2H, NH₂), 6.42 (*s*, 2H, Ar-H),
 107 7.41 (*s*, 1H, NH), 10.05 (*s*, 2H, Ar-OH). ¹³C NMR (100 MHz, CDCl₃): 24.4 (CH₃, C-8), 99.7 (C,
 108 C-1), 112.2 (CH, C-3/5), 144.7 (C, C-4), 164.0 (C, C-2/6), 166.5 (C, C-7). MS (EI, 70 eV): *m/z*
 109 (%) = 183.35 [M + H⁺]. HRMS-FAB: *m/z* [M + H⁺] calcd for C₈H₁₀N₂O₃: 182.18; found: 182.35.
 110 Anal. Calcd for C₈H₁₀N₂O₃: C, 52.74; H, 5.53; N, 15.38. Found C, 52.64; H = 5.52; N = 15.48.



4b

111


112 (*E*)-2,6-dihydroxy-*N'*-(4-methoxybenzylidene)-4-methylbenzohydrazide (*4b*). Product
 113 yield: 68%, MP: 120-121°C. IR (KBr): 3205, 3054, 2843, 1655, 1804, 1509, 1462, 1428, 1379,
 114 1340, 1300, 1250, 1171, 1096, 1028, 960, 761, 668 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): 2.38 (*s*,
 115 3H, Me), 3.84 (*s*, 3H, OMe), 6.37-6.38 (*d*, 2H, Ar-H), 6.91-6.93 (*m*, 2H, Ar-H), 7.60-7.62 (*m*,
 116 2H, Ar-H), 7.78 (*s*, 1H, =CH), 9.89 (*s*, 2H, Ar-OH). ¹³C NMR (400 MHz, CDCl₃): 20.4 (CH₃, C-
 117 8), 55.4 (CH₃, C-16), 111.5 (C, C-1), 114.2 (CH, C-3/5), 126.6 (CH, C-12/14), 128.7 (C, C-10),
 118 138.3 (CH, C-11/15), 143.8 (C, C-4), 147.3 (CH, C-9), 161.2 (C, C-2/6), 164.4 (C, C-13), 174.1
 119 (C, C-7). MS (EI, 70 eV): *m/z* (%) = 301.15 [M + H⁺] (100). HRMS-FAB: *m/z* [M + H⁺] calcd
 120 for C₁₆H₁₆N₂O₄: 300.31; found: 300.15. Anal. Calcd for C₁₆H₁₆N₂O₄: C, 63.99; H, 5.37, N, 9.33.
 121 Found C, 64.00; H = 5.32; N = 9.37.



4c

122

123 (*E*)-*N'*-butylidene-2,6-dihydroxy-4-methylbenzohydrazide (*4c*). Product yield: 70%, MP:
 124 110-111°C. IR (KBr): 3814, 3217, 3066, 2973, 2934, 1457, 1379, 1341, 1287, 1167, 1101, 846,
 125 769 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): 0.95-1.03 (*m*, 3H, Me), 1.91-1.93 (*m*, 2H, CH₂), 2.15 (*s*,
 126 3H, Me), 2.18-2.20 (*m*, 2H, CH₂), 6.51 (*s*, 2H, Ar-H), 7.19-7.21 (*t*, 1H, =CH), 7.83 (*s*, 1H, NH)
 127 10.14 (*s*, 2H, Ar-OH). ¹³C NMR (400 MHz, CDCl₃): 14.2 (CH₃, C-12), 19.8 (CH₂, C-11), 22.7
 128 (CH₃, C-8), 29.8 (CH₂, C-10), 106.5 (C, C-1), 113.9 (CH, C-3/5), 130.5 (C, C-4), 149.5 (CH, C-
 129 9), 155.8 (C, C-2/6), 168.6 (C, C-7). MS (EI, 70 eV): *m/z* (%) = 237.15 [M + H⁺]. HRMS-FAB:
 130 *m/z* [M + H⁺] calcd for C₁₂H₁₆N₂O₃: 236.27; found: 236.15. Anal. Calcd for C₁₂H₁₆N₂O₃: C,
 131 61.00; H, 6.83, N, 11.89. Found C, 61.00; H = 6.80; N = 11.89.




4d

132


133 (*E*)-*N'*-benzylidene-2,6-dihydroxy-4-methylbenzohydrazide (*4d*). Product yield: 64%, MP:
 134 98-99°C. IR (KBr): 3183, 3077, 2969, 2858, 1669, 1605, 1500, 1393, 1338, 1224, 1133, 1016,
 135 948, 899, 758, 685 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): 2.40 (*s*, 3H, Me), 7.39-7.40 (*m*, 3H, Ar-
 136 H), 7.67-7.68 (*m*, 2H, Ar-H), 7.84 (*d*, 1H, =CH), 8.84 (*s*, 1H, NH), 10.02 (*s*, 2H, Ar-OH). ¹³C

137 NMR (400 MHz, CDCl₃): 20.4 (CH₃, C-8), 105.6 (C, C-1), 112.3 (CH, C-3/5), 127.2 (CH, C-
 138 12/14), 128.8 (CH, C-11/13/15), 130.1 (C, C-10), 133.9 (C, C-4), 143.8 (CH, C-9), 165.5 (C, C-
 139 2/6), 174.2 (C, C-7). MS (EI, 70 eV): *m/z* (%) = 271.25 [M + H⁺]. HRMS-FAB: *m/z* [M + H⁺]
 140 calcd for C₁₅H₁₄N₂O₃: 270.29; found: 470.25. Anal. Calcd for C₁₅H₁₄N₂O₃: C, 66.66; H, 5.20, N,
 141 10.36. Found C, 66.68; H = 5.20, N = 10.40.



142
 143 (*E*)-*N'*-(3,5-dichlorobenzylidene)-2,6-dihydroxy-4-methylbenzohydrazide (*4e*). Product
 144 yield: 75%, MP: 130-131°C. IR (KBr): 3082, 2954, 1687, 1595, 1519, 1466, 1385, 1332, 1276,
 145 1217, 1152, 1097, 1020, 927, 860, 816, 769, 665 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): 2.38 (*s*, 3H,
 146 Me), 7.27-7.29 (*m*, 2H, Ar-H), 7.41-7.42 (*m*, 1H, Ar-H), 7.91-7.93 (*m*, 1H, =CH), 8.12 (*s*, 1H,
 147 NH), 9.37 (*s*, 2H, Ar-OH). ¹³C NMR (400 MHz, CDCl₃): 20.4 (CH₃, C-8), 104.4 (C, C-1), 112.1
 148 (CH, C-3/5), 127.9 (CH, C-11/15), 129.9 (CH, C-13), 134.6 (C, C-12/14), 136.3 (C, C-10), 138.7
 149 (C, C-4), 142.3 (CH, C-9), 159.5 (C, C-2/6), 173.4 (C, C-7). MS (EI, 70 eV): *m/z* (%) = 340.15
 150 [M + H⁺]. HRMS-FAB: *m/z* [M + H⁺] calcd for C₁₅H₁₂Cl₂N₂O₃: 339.17; found: 339.15.


151



152

153


Figure S1: ¹H NMR of **1** (400 MHz, CDCl₃)



154

155

Figure S2: ¹³C NMR of **1** (400 MHz, CDCl₃)



156

157

Figure S3: FT-IR of **1** (KBr)


Qualitative Analysis Report

Data Filename	RL-01.d	Sample Name	RL-01
Sample Type	Sample	Position	Vial 11
Instrument Name	Instrument 1	User Name	
Acq Method		Acquired Time	7/22/2017 11:56:56 PM
IRM Calibration Status	Not Applicable	DA Method	raghu.m

Comment


User Chromatograms

Fragmentor Voltage 135 **Collision Energy** 0 **Ionization Mode** ESI



User Spectra

Fragmentor Voltage 135 **Collision Energy** 0 **Ionization Mode** Esi




Peak List

m/z	z	Abund
343	1	399846
344	1	73057
426.8		39659
675.2		21883
708.9	1	60823
709.9	1	24969

Fragmentor Voltage 135 **Collision Energy** 0 **Ionization Mode** Esi

Figure S4: ESI-MS of 1

Qualitative Analysis Report



Peak List

m/z	z	Abund
123.1		129023
124.1	1	75959
125.2	1	7426
139.1		30354
149		12675
219.1		31120
260.1		11611
290		8991
345	1	32807
593.9		10264


--- End Of Report ---

160

161

162

Figure S4a: ESI-MS of 1



167

168

169

Figure S7: FT-IR of 2 (KBr)


Qualitative Analysis Report

Data Filename	RL-05.d	Sample Name	RL-05
Sample Type	Sample	Position	Vial 7
Instrument Name	Instrument 1	User Name	
Acq Method		Acquired Time	7/22/2017 11:37:44 PM
IRM Calibration Status	Not Applicable	DA Method	raghu.m

Comment


User Chromatograms

Fragmentor Voltage 135 **Collision Energy** 0 **Ionization Mode** ESI



User Spectra

Fragmentor Voltage 135 **Collision Energy** 0 **Ionization Mode** Esi



Peak List

<i>m/z</i>	<i>z</i>	Abund
165.1		203259
209.1	1	1274073
210.1	1	127513
441		70451


Fragmentor Voltage 135 **Collision Energy** 0 **Ionization Mode** Esi

170

171

Figure S8: ESI-MS of 2

Qualitative Analysis Report



Peak List

m/z	z	Abund
123		63741
124.1	1	143809
139.1		41215
149		25343
193		18383
211		22719
219.2		26732
290		21302
408.7		15573
418.9		33641


--- End Of Report ---

172

173

174


Figure S8a: ESI-MS of 2



175

176


Figure S9: ¹H NMR of 3 (400 MHz, DMSO-*d*₆)



177

178

Figure S10: ¹³C NMR of 3 (400 MHz, DMSO-*d*₆)



179

180

181


Figure S11: FT-IR of 3 (KBr)

Qualitative Analysis Report

Data Filename	RL-03.d	Sample Name	RL-03
Sample Type	Sample	Position	Vial 8
Instrument Name	Instrument 1	User Name	
Acq Method		Acquired Time	7/22/2017 11:42:29 PM
IRM Calibration Status	Not Applicable	DA Method	raghu.m


Comment
User Chromatograms

Fragmentor Voltage 135 **Collision Energy** 0 **Ionization Mode** ESI



User Spectra

Fragmentor Voltage 135 **Collision Energy** 0 **Ionization Mode** ESI



Peak List

m/z	z	Abund
209.1		147727
225.1		75530
249.3		81514
417	1	811707
418	1	196038


Fragmentor Voltage 135 **Collision Energy** 0 **Ionization Mode** ESI

182

183

Figure S12: ESI-MS of 3


Qualitative Analysis Report



Peak List

m/z	z	Abund
124.1		40435
193.1	1	385107
194.1	1	43770
365.1		245120
418.9		40017
610.9		38456
853.7	1	44233
854.8	1	24743


--- End Of Report ---



187

188


Figure S13: ^1H NMR of **4** (400 MHz, $\text{DMSO-}d_6$)



189

190

Figure S14: ^{13}C NMR of **4** (400 MHz, $\text{DMSO-}d_6$)




191

192

Figure S15: FT-IR of 4 (KBr)

6/10/2016 12:06:31 PM Page 1 / 1

==== Organic and Biomolecular Chemistry Division, IICT ====




193

194

Figure S16: ESI-MS of 4


D:\Data\MASS\JUN -2016\09-RM-01.lcd



195

196

Figure S17: ^1H NMR of **5** (400 MHz, CDCl_3)




197

198

Figure S18: ^{13}C NMR of **5** (400 MHz, CDCl_3)


RSP-MAL-05 #8-19 RT: 0.06-0.15 AV: 12 NL: 7.28E6
T: FTMS {1,1} + p ESI Full ms [75.00-1500.00]



199

200


Figure S20: ESI-MS of 5



201

202


Figure S21: ¹H NMR of 4a (400 MHz, CDCl₃)



203

204

Figure S22: ^{13}C NMR of **4a** (400 MHz, CDCl_3)



205


206

Figure S23: FT-IR of **4a** (KBr)

Sample Name : BSR-11-168
Data File : 030418.101.lcd
Date Acquired : 4/3/2018 6:51:34 PM
Batch File : 03-04-2018.lcb

MS Spectrum
D:\DATA\MARCH-2018\030418.101.lcd

Averaged ESI+ Positive
Spectrum Mode Averaged 0.188-0.427 (91-206)




1

207

208


209

Figure S24: ESI-MS of 4a (positive mode)

210

211


Figure S25: 1H NMR of 4b (400 MHz, $CDCl_3$)



212

213

Figure S26: ^{13}C NMR of **4b** (400 MHz, CDCl_3)



214


215

Figure S27: FT-IR of **4b** (KBr)

Sample Name : BSR-BA-168
Data File : 030418.56.lcd
Date Acquired : 4/3/2018 5:39:08 PM
Batch File : 03-04-2018.lcb

MS Spectrum
D:\DATA\MARCH-2018\030418.56.lcd


Average ESI Positive
Spectrum Mode Averaged 0.160-0.321(78-155)
[CPS]



216

217


Figure S28: ESI-MS of **4b** (positive mode)



218

219


Figure S29: ¹H NMR of **4c** (400 MHz, CDCl₃)



220

221

Figure S30: ^{13}C NMR of 4c (400 MHz, CDCl_3)



222


223

Figure S31: FT-IR of 4c (KBr)

Sample Name : BSR-B-222
Data File : 030418.81.lcd
Date Acquired : 4/3/2018 6:19:15 PM
Batch File : 03-04-2018.lcb

MS Spectrum
D:\DATA\MARCH-2018\030418.81.lcd


Averaged ESI Positive
Spectrum Mode Averaged 0.190-0.429(92,207)
[CPS]



224

225


Figure S32: ESI-MS of **4c** (positive mode)



226

227


Figure S33: ¹H NMR of **4d** (400 MHz, CDCl₃)



228

229

Figure S34: ^{13}C NMR of **4d** (400 MHz, CDCl_3)



230


231

Figure S35: FT-IR of **4d** (KBr)

Sample Name : BSR-C-256
Data File : 030418.77.lcd
Date Acquired : 4/3/2018 6:12:53 PM
Batch File : 03-04-2018.lcb

MS Spectrum
D:\DATA\MARCH-2018\030418.77.lcd


Averaged ESI Positive-
Spectrum Mode Averaged 0.221-0.381(107-184)
[CPS]



232

233


Figure S36: ESI-MS of 4d (positive mode)



234

235


Figure S37: 1H NMR of 4e (400 MHz, $CDCl_3$)



236

237

Figure S38: ^{13}C NMR of **4e** (400 MHz, CDCl_3)



238


239

Figure S39: FT-IR of **4e** (KBr)

Sample Name : BSR-D-325
 Data File : 030418.86.lcd
 Date Acquired : 4/3/2018 6:29:07 PM
 Batch File : 03-04-2018.lcb

MS Spectrum
 D:\DATA\MARCH-2018\030418.86.lcd

Averaged ESI Positive+
 Spectrum Mode: Averaged 0.177-0.413(86-199)
 [CPS]




1

241

242

Figure S40: ESI-MS of **4e** (positive mode)

243



244

Figure S41: Diameter of zones of inhibition values for all the isolates and benzohydrazide

246

derivatives of *Ramalina leiodea* against bacterial and fungal stains.



247

248 **Figure S42:** *In vitro* anti-tubercular activity of all the isolates and benzohydrazide derivatives of
 249 *Ramalina leiodea* against *Microbacterium tuberculosis* H37Rv strain.

250

REFERENCES

251 1. P. R. Shetty, S. K. Buddana, V. B. Tatipamula, Y. V. V. Naga, J. Ahmad, *Braz. J.*
 252 *Microbiol.* **45** (2014) 303-312 (<https://doi.org/10.1590/S1517-83822014005000022>)

- 253 2. V. B. Tatipamula, G. S. Vedula, B. B. Rathod, P. R. Shetty, A. V. S. Sastry, *Inventi*
254 *Impact: Planta Activa* **2018** (2018) 129
255 (<http://inventi.in/journal/article/impact/61/25058/planta-activa/ci>)
256 3. K. R. Paidi, V. B. Tatipamula, M. K. Kolli, V. R. Pedakotla, *International Journal of*
257 *Chemical Sciences* **15** (2017), 172 (0972-768X).
258